Table 2.
PectinSource and Modification | In Vivo Model | In Vitro Model | Galectin-3 Blocking | Main Results | Reference |
---|---|---|---|---|---|
Citrus (pH and temperature-modified pectin) 1% in drinking water |
NCR nu/nu mice injected with LSLiM6 cells |
- | ↓ binding to HUVEC ↓ HUVEC chemotaxis/ capillary tube formation |
Therapeutic effect: ↓ tumor growth ↓tumor- associated blood vessels ↓ NM and LM |
[114] |
Citrus (modified pectin) 1–5% in drinking water |
Balb/c mice spleen injected with CT26 cells | - | = expression in blood and LM | Therapeutic effect: ↓ tumor growth ↓ LM |
[115] |
Citrus(LMW pectin PYKTIN, Centrax Int.) 1–5% in drinking water |
Nude mice engrafted with SW-480 cells | - | ↓ expression | Therapeutic effect: ↓ tumor growth ↑ 5-FU effect ↑ apoptosis in tumor tissue |
[116] |
Citrus(modified pectin with alginate and L. acidophilus) | AOM-treated Balb/c mice | - | ↓ expression in colonic crypts and blood vessels | Chemopreventive effect: ↓ precancerous lesions |
[117] |
Apple(modified pectin from red Fuji apples) 2.5–10% in pellet diet |
DMH/DSS- treated ICS mice |
- | ↓ expression in serum ↓ galactose binding to SW-1116 |
Chemopreventive effect: ↓ colon inflammation ↓ tumorigenesis ↑ colonic EC apoptosis ↑ caspase-3 activation |
[118] |
Smilax china L. (pectin) |
DSS-treated Balb/c mice | - | ↓ Gal- 3/NLRP3 inflammasome interaction |
Therapeutic/preventive effects: ↓ UC histo- pathological damage ↓ inflammatory mediators |
[3] |
Citrus(modified pectin, EcoNugenics) 0.1–25 mM |
- | DLD-1 | ↓ extracellular expression | ↓ cell migration | [81] |
Citrus (LMW pectin PYKTIN, Centrax Int.) 0.625–10 mg/mL |
- | SW-480 | ↓ expression | ↓ cell proliferation ↑ cell cycle arrest ↓ EMT |
[116] |
Ginseng (HG-rich pectin) Ginseng(temperature-modified pectin) |
- | HT-29 HT-29 |
ND | ↓ cell proliferation ↑ cell cycle arrest ↓↓ cell proliferation ↑ apoptosis ↑ caspase-3 activation |
[119] |
ND | |||||
Ginseng (RG-I-4 pectic fragment) |
- | HT-29 | ↓ rGal3- induced RBC agglutination ↓ binding to Jurkat cells |
↓ cell adhesion ↓ ASF-induced cell aggregation |
[120] |
Apple(enzyme- modified, enriched in RG-I regions) |
- | HCT 116 Caco-2 HT-29 |
↓ expression | ↑ irinotecan effect ↓ cell viability ↑ apoptosis ↑ ROS ↓ LPS-induced inflammatory mediators |
[121] |
Sugar beet(enzyme- or alkali- modified pectin) 0.2–1 mg/mL |
- | HT-29 DLD-1 |
Galactose/ arabinose- mediated |
↓ cell proliferation ↑ apoptosis |
[122] |
Olive (heat- and acid-modified pectin) 1–10 mg/mL |
- | Caco-2 | ↓ rGal3-induced RBC agglutination | ↓ cell proliferation | [123] |
Jaboticaba (pectin from fruit flour) 0.25–2 mg/mL |
- | HCT116 | ↓ rGal3- induced RBC agglutination |
↓ cell viability | [124] |
Papaya (pectin from fruit pulp) 0.025–0.2% |
- | HCT116 HT-29 |
↓ rGal3- induced RBC agglutination Gal-3 gene knockdown |
↓ cell viability ↓ cell proliferation |
[108,125] |
Abbreviations: AOM, azoxymethane; ASF, asialofetuin; DMH, 1,2-dimethylhydrazine; DSS, dextran sodium sulfate; NDC, non-digestible carbohydrates; EC, epithelial cells; EMT, epithelial–mesenchymal transition; 5-FU, 5-fluorouracil; HG, homogalacturonan; LMW, low molecular weight; LPS, lipopolysaccharide; LM, liver metastases; NM, node metastases; RBC, red blood cells; rGal3, recombinant galectin 3; ROS, reactive oxygen species; UC, ulcerative colitis.